title: The Cost Burden of Switching Patients with Relapsing-Remitting Multiple Sclerosis from Glatiramer Acetate To Newly-Approved Disease Modifying Therapies.
authors.affiliation: Covance Inc., London, UK.
authors.forename: M
authors.initials: M
authors.lastname: Blackney
authors.affiliation: Covance, Inc., London, UK.
authors.forename: M
authors.initials: M
authors.lastname: Kelly
authors.affiliation: Covance, Inc., London, UK.
authors.forename: R
authors.initials: R
authors.lastname: Zeidman
authors.affiliation: Teva Pharmaceuticals Europe B. V., Amsterdam, The Netherlands.
authors.forename: M
authors.initials: M
authors.lastname: Andreykiv
authors.affiliation: Teva Pharmaceuticals Europe B. V, Amsterdam, The Netherlands.
authors.forename: A
authors.initials: A
authors.lastname: Plich